Enopeptin approved for adult weight management in China

Pfizer China announced today that the National Medical Products Administration (NMPA) has officially approved the new generation cAMP-biased GLP-1 receptor agonist, Enopeglutide injection, for long-term weight management in adult overweight/obese patients based on dietary control and increased physical activity.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin